Arcadia Biosciences
RKDA
11 hedge funds and large institutions have $1.79M invested in Arcadia Biosciences in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 5 closing their positions.
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
21% less capital invested
Capital invested by funds: $2.26M → $1.79M (-$469K)
27% less funds holding
Funds holding: 15 → 11 (-4)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$38.1K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.8K |
| 3 |
VF
Virtu Financial
New York
|
+$6.96K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$3.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LRPA
L. Roy Papp & Associates
Phoenix,
Arizona
|
-$333K |
| 2 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$77.3K |
| 3 |
Goldman Sachs
New York
|
-$6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4K |
| 5 |
BlackRock
New York
|
-$2.56K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WRF
1
Waddell & Reed Financial
Overland Park,
Kansas
| $1.63M | -$77.3K | -211 | -4% |
|
|
2
Renaissance Technologies
New York
| $59K | +$38.1K | +104 | +146% |
|
|
3
Vanguard Group
Malvern,
Pennsylvania
| $41K | +$12.8K | +35 | +41% |
|
4
Creative Planning
Overland Park,
Kansas
| $19K | – | – | – |
|
|
BCM
5
Bridgeway Capital Management
Houston,
Texas
| $17K | – | – | – |
|
6
Geode Capital Management
Boston,
Massachusetts
| $11K | – | – | – |
|
7
Northern Trust
Chicago,
Illinois
| $7K | – | – | – |
|
|
VF
8
Virtu Financial
New York
| $6K | +$6.96K | +19 | New |
|
|
9
UBS Group
Zurich,
Switzerland
| $3K | +$3.3K | +9 | New |
|
|
10
BlackRock
New York
| $2K | -$2.56K | -7 | -58% |
|
|
FDCDDQ
11
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $4 | – | – | – |
|
|
LRPA
12
L. Roy Papp & Associates
Phoenix,
Arizona
| – | -$333K | -925 | Closed |
|
|
13
Goldman Sachs
New York
| – | -$6K | -16 | Closed |
|
|
TRCT
14
Tower Research Capital (TRC)
New York
| – | -$4K | -11 | Closed |
|
15
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$1K | -3 | Closed |
|
RKDA Hedge Fund Activity: Q3 2017 in Review
11 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Arcadia Biosciences (RKDA) for Q3 2017, worth a combined $1.79M — down 21% from $2.26M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of RKDA and 2 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, adding an estimated $38.1K. The largest seller was L. Roy Papp & Associates, exiting entirely with an estimated $333K sold.
- 11 institutional investors held Arcadia Biosciences (RKDA) as of Q3 2017, down from 15 in Q2 2017.
- Funds reported $1.79M of Arcadia Biosciences stock for Q3 2017, down 21% quarter-over-quarter.
- 2 funds opened new Arcadia Biosciences positions in Q3 2017 and 5 closed out, a net change of -3 holders.
- The largest Arcadia Biosciences buyer in Q3 2017 was Renaissance Technologies, an estimated $38.1K added.
- The largest Arcadia Biosciences seller in Q3 2017 was L. Roy Papp & Associates, an estimated $333K sold.
Based on aggregated 13F filings for Q3 2017.